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The molecular etiology of uterine leiomyosarcoma (ULMS) is poorly understood, which accounts for the wide
disparity in outcomes among women with this disease. We examined and compared the molecular profiles of
ULMS and normal myometrium (NL) to identify clinically relevant molecular subtypes. Discovery cases included 29
NL and 23 ULMS specimens. RNA was hybridized to Affymetrix U133A 2.0 transcription microarrays. Differentially
expressed genes and pathways were identified using standard methods. Fourteen NL and 44 ULMS independent
archival samples were used for external validation. Molecular subgroups were correlated with clinical outcome.
Pathway analyses of differentially expressed genes between ULMS and NL samples identified overrepresentation
of cell cycle regulation, DNA repair, and genomic integrity. External validation confirmed differential expression in
31 genes (P b 4.4 × 10−4, Bonferroni corrected), with 84% of the overexpressed genes, including CDC7, CDC20,
GTSE1, CCNA2, CCNB1, and CCNB2, participating in cell cycle regulation. Unsupervised clustering of ULMS
identified two clades that were reproducibly associated with progression-free (median, 4.0 vs 26.0 months; P =
.02; HR, 0.33) and overall (median, 18.2 vs 77.2 months; P= .04; HR, 0.33) survival. Cell cycle genes play a key role
in ULMS sarcomagenesis, providing opportunities for therapeutic targeting. Reproducible molecular subtypes
associated with clinical outcome may permit individualized adjuvant treatment after clinical trial validation.
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Uterine leiomyosarcoma (ULMS), the most common subtype of
uterine sarcoma, is a rare tumor, with an annual incidence of 0.64 per
100,000 women [1]. ULMS is aggressive, with a propensity for
hematogenous spread leading to local and distant recurrence [2–5].
Surgery is the primary treatment modality, and tumors are often
resistant to both chemotherapy and radiation therapy [6,7]. To date,
adjuvant therapy has not demonstrated a significant survival
advantage. Although surgical staging and nomograms can help
predict clinical outcome, the 5-year survival rate for uterus-confined
disease remains less than 50% [2,8]. It is difficult to predict the
clinical course of ULMS, even when considering clinical and
pathologic factors beyond surgical staging. Understanding the
molecular biology of ULMS may provide further prognostic and
therapeutic insights.
In attempts to understand the pathobiology of ULMS, compar-
isons have been made to both normal myometrium (NL) and benign
uterine leiomyomata. Genome-wide profiling has clustered ULMS,
leiomyomas, and NL, demonstrating differences in expression profiles
[9]. Immunohistochemistry has also shown differential expression of
apoptotic and cell cycle regulatory proteins in ULMS compared to
benign smooth muscle tumors [10]. We have previously reported that
microRNA profiling supports divergent transformation pathways
from normal to benign leiomyoma or ULMS, with ULMS
phylogenetically more similar to mesenchymal stem cells than
established leiomyomata [11]. The variable and unpredictable
behavior of morphologically similar ULMS confined to the uterus
supports the need for clinically relevant molecular subtyping.
Previous reports have often included uterine and non-ULMS tumors
comparing malignant and benign tissues or searching for clinical
associations with a variety of study designs [12–14].
Given the wide disparity in outcomes among women with ULMS
and the lack of benefit from adjuvant therapy, we performed gene
expression profiling on a homogeneous, single-institution set of
ULMS without inclusion of tumors from non-gynecologic sites of
origin. We tested the hypothesis that ULMS has distinct molecular
subtypes that are associated with clinical outcome and may identify
therapeutic targets.
Methods
Patient Samples
Frozen and archival formalin-fixed and paraffin-embedded (FFPE)
biospecimens were obtained from the tissue repositories at Memorial
Sloan Kettering Cancer Center (MSKCC) after Institutional Review
Board approval. A gynecologic oncology specialty pathologist
reviewed all primary surgical resection specimens. NL and leiomyo-
mata from patients undergoing hysterectomy for benign indications
were used for comparison. A discovery cohort of fresh frozen tissues
included 29 NL, 25 leiomyomata, and 23 consecutive ULMS
specimens collected between 1998 and 2006.
External validation was performedwith 46 additionalULMS samples
and 14 NL samples. The ULMS samples were consecutive FFPE
samples collected between 1998 and 2006. The 14 NL samples were a
convenience subset of patients undergoing surgery for benign
indications during the same time period. A subset of 29 ULMS cases
was used initially to replicate differential expression betweenULMS and
NL. Two of the ULMS cases were expired during this analysis, leaving
44 ULMS cases to confirm the reproducibility of ULMS clades.Gene Expression Profiling
RNA was extracted from frozen NL, leiomyoma, and ULMS
biospecimens using Ambion mirVana miRNA Isolation Kit (Life
Technologies, Grand Island, NY). RNA was quantified and quality
assessed using an Agilent Bioanalyzer 2100 at MSKCC and then
hybridized to Affymetrix U133A 2.0 human genome microarrays
(Affymetrix, Santa Clara, CA) for global mRNA gene expression
profiling (Gene Expression Omnibus Series accession number
GSE64763). All samples had RIN values N7.0.
RNA for the external validation cohorts was extracted from FFPE
tissues using the Ambion RecoverAll Total Nucleic Acid Isolation Kit
(Life Technologies). Fragment size was assessed using the Agilent
Bioanalyzer 2100 at MSKCC to ensure adequate lengths N300
nucleotides sufficient for hybridization. The NanoString nCounter
gene expression system was used for external validation from FFPE
biospecimens (NanoString Technologies, Seattle, WA). NanoString
technology captures and counts individual mRNA transcripts without
the need for enzymatic amplification [15]. Briefly, two probes were
designed for each gene of interest complementary to a 100-base region of
the target mRNA. Each sample was hybridized in triplicate. Fluorescent
barcodes were counted using the nCounter Digital Analyzer. All genes
and controls were assayed simultaneously in a multiplex reaction.
To externally validate the differentially expressed genes between
ULMS and NL, RNA was hybridized to a NanoString code set of 90
genes with more than four-fold differential expression in the discovery
cohort. A separate NanoString nCounter gene expression custom
code set of 73 genes differentially expressed between the ULMS clades
was selected on the basis of fold change and known function to cluster
the 44 external validation ULMS samples.
Microarray Data Analysis
Microarray data from the discovery cohort was normalized with
robust multi-array average [16].
Unsupervised hierarchical clustering using Euclidean distance and
Ward linkage was performed to identify potential subgroups among the
samples. ULMS subgroups identified from unsupervised clustering were
compared using a modified t test to identify subgroup signature genes.
Signature genes distinguishing the two sample clusters were selected using
the t test P values as a ranking criterion and a cutoff of 0.001 [17].
Supervised class comparison generated differentially expressed
genes between ULMS and NL samples using a modified t test [17].
False discovery rate (FDR) was calculated to adjust for multiple
comparisons among the ~22,000 markers on the U133 2.0 array, and
an FDR cutoff of 0.0001 was used to select genes that were
significantly differentially expressed between ULMS and NL [18].
Ingenuity Pathway Analysis identified overrepresented pathways and
networks from the differentially expressed genes. We used GSEA to
evaluate differentially expressed genes between tumor and normal
samples and between the identified ULMS molecular subtypes [19].
All curated gene sets (MSigDB c2 collection) of size 15 to 300 genes
(N = 2294 gene sets) were evaluated. To account for gene-gene
correlations in the enrichment analysis, GSEA gene set enrichment
P values were computed with respect to a null distribution obtained
from 100,000 randomizations of the patient-phenotype labels.
NanoString Data Analysis
The nCounter Digital Analyzer quantified RNAmolecules of interest,
and raw data were normalized to account for differences in hybridization
and purification efficiency using 10 control genes in each custom code set.
Neoplasia Vol. 17, No. 2, 2015 Molecular Subtypes of Uterine Leiomyosarcoma Barlin et al. 185A two-sample t test was performed to identify genes that were
differentially expressed between NL and ULMS samples. Bonferroni
correction was used to adjust for multiple hypothesis testing among
the relatively small set of genes profiled by NanoString.
To confirm the results from unsupervised hierarchical clustering of
the discovery cohort samples based on the Affymetrix U133A 2.0
array data, we tested whether the same clade assignments could be
made using a select code set of 73 differentially expressed genes to re-
cluster the same discovery cohort samples.
These 73 genes were then used to cluster an external validation set
of ULMS samples. Consensus clustering was used to assess the
reproducibility of the clusters based on bootstrapping [20].
Outcome Analyses
Primary and recurrent samples were analyzed separately to eliminate
lead-time bias. For primary surgical patients, recurrence-free survival
(RFS) was defined as the time from initial surgical resection to date of first
recurrence or last disease assessment; overall survival (OS) was defined as
the time from initial surgical resection to the date of death or last follow-
up. For recurrent patients, the survival interval started from the time that
the recurrent sample was obtained and continued until the date of
subsequent recurrence or last disease assessment; OS was defined as the
time the recurrent sample was obtained to the date of death or last follow-
up. Among both primary and recurrent patients, no patient died without
recurrence or progression.
After assigning the discovery and external validation cohorts into
molecular subgroups, estimates of median RFS and OS were obtained
for each subgroup using the methods of Kaplan and Meier [21]. RFS
and OS were compared between subgroups using the log-rank test
and Cox proportional hazards model, as appropriate.
Results
Patient Characteristics
The 67 patients with ULMS had a median age of 53 years (range,
26-80). The tumors were from primary resections in 36% of cases and
from recurrent resections in 64%. Most tumors were high grade
(91%) and stage I (60%). See Table 1 for the complete clinical and
pathologic features of the ULMS cases.Table 1. Patient Characteristics for ULMS Cases and Clades
Characteristic Clade 1 Clade 2 Total P Value *
Number of patients 23 (34%) 44 (66%) 67
Age .20
Median (range) 54.8 (41–73) 51.6 (26–80) 53.0 (26–80)
Specimen source .88
Primary specimen 9 (39%) 15 (34%) 24 (36%)
Recurrent specimen 14 (61%) 29 (66%) 43 (64%)
Grade (one missing) .24
Low 0 5 (11%) 5 (8%)
High 22 (100%) 39 (89%) 61 (91%)
FIGO stage .90
I 13 (57%) 27 (61%) 40 (60%)
II/III/IV 10 (43%) 17 (39%) 27 (40%)
Primary tumor size (six missing) .53
≤10 cm 9 (43%) 22 (55%) 31 (51%)
N10 cm 12 (57%) 18 (45%) 30 (49%)
Mitotic index (17 missing) .86
≤20 11 (73%) 23 (66%) 34 (68%)
N20 4 (27%) 12 (34%) 16 (32%)
Adjuvant treatment 1
No 16 (70%) 32 (73%) 48 (72%)
Yes 7 (30%) 12 (27%) 19 (28%)
* P values were obtained by using Student's t test for age and Fisher's exact test for the other variables.Gene Expression Analyses
Unsupervised hierarchical clustering of the discovery cohort
identified clear separation of ULMS, leiomyoma, and NL samples
(Figure 1). One clade contained 18 ULMS samples with no
leiomyoma or NL samples. Five (22%) of the 23 discovery ULMS
samples fell into the predominantly leiomyoma clade, which also
contained 2 (7%) of the 29 NL discovery samples. The NL clade
contained 6 (24%) of the 25 leiomyoma discovery samples but no
ULMS samples. Class comparison identified 3929 differentially
expressed genes (2114 upregulated and 1815 downregulated)
between ULMS and NL at an FDR of 0.0001 (Table S1). Pathway
analyses of these 3929 genes identified overrepresentation in the
regulation of the cell cycle, DNA repair, and genomic integrity.
Unsupervised clustering of ULMS samples identified two main
clades, with 7 samples in clade 1 and 11 samples in clade 2. A
supervised analysis of these two clades identified 251 differentially
expressed genes at P b .001 (Table S2).
To validate the differentially expressed genes between LMS and NL,
90 geneswithmore than a four-fold difference in expression and an FDR
of less than 1 × 10−9 were chosen from the discovery cohort for external
validation in an independent cohort of 43 samples. After Bonferroni
correction for multiple hypothesis testing, 19 genes had significantly
greater expression and 12 genes had significantly less expression in LMS
compared to NL (P b 4.4 × 10−4 for all; Table S3). Sixteen (84%) of the
19 overexpressed genes, including CDC7, CDC20, GTSE1, CCNA2,
CCNB1, and CCNB2, were involved in cell cycle regulation, suggesting
the importance of this biologic mechanism in sarcomagenesis.
From the 251 differentially expressed genes between the two
ULMS clades, a separate NanoString code set was designed for
validation, which included 73 genes chosen based on fold change,
FDR, and biologic significance (Table S2). All of the discovery cohort
samples were reproducibly clustered into the same clades using the
subset of 73 genes, confirming the unsupervised analysis originally
obtained from the full set of U133A 2.0 microarray data. The clades
were also reproducible when separately analyzing the primary and
recurrent discovery specimens. This 73-gene code set was then
applied to an independent validation set of 44 ULMS samples and
reproduced the two ULMS clades (Figure S1). In the validation
cohort, the clade assignments also remained stable when separately
analyzing the primary and recurrent samples. Consensus clustering
confirmed clade reproducibility through permutation testing using
random resampling and bootstrapping (Figure S2).
Gene Set Enrichment Analysis
The gene set enrichment analysis (GSEA) detailed results can be
found at http://cbio.mskcc.org/~ajac/leio/ and are illustrated in part
in Figure S3. We determined enrichment from a database of curated
pathways and gene sets, and we evaluated the significance of
enrichment by permutation of patient-phenotype labels to account
for dependencies between individual gene expression profiles.
Genes upregulated in tumor relative to normal samples had
enrichment of many cell cycle associated gene sets and significant
(adjusted P = .04) enrichment of a set of genes previously found to be
upregulated in high-grade papillary urothelial bladder cancer (Table
S4) [22]. Genes downregulated in tumors showed strongest
enrichment for a set of genes previously found to be downregulated
in mucinous ovarian carcinoma; however, this was not significant
after correction for multiple hypothesis testing, suggesting weak or
spurious association (Table S5) [23].
Figure 1. Unsupervised hierarchical clustering of the discovery cohort.
Table 2. Demographic and Association Table for Primary Tumors
All Patients Clade 1 Clade 2 P Value *
All 24 9 15
Age at diagnosis
Median (mean) 55.5 (55) 57 (59.9) 52 (52.1) .16
Range 26-73 53-73 26-72
FIGO stage
I 14 (58%) 4 (44%) 10 (67%) .40
II/III/IV 10 (42%) 5 (56%) 5 (33%)
Grade
Low 2 (8%) 0 (0%) 2 (13%) .51
High 22 (92%) 9 (100%) 13 (87%)
Size
≤10 cm 13 (54%) 4 (44%) 9 (60%) .68
N10 cm 11 (46%) 5 (56%) 6 (40%)
Mitotic index (five missing)
≤20 13 (68%) 4 (67%) 9 (69%) 1
N20 6 (32%) 2 (33%) 4 (31%)
Adjuvant therapy
No 17 (71%) 6 (67%) 11 (73%) 1
Yes 7 (29%) 3 (33%) 4 (27%)
* P values were obtained by using Wilcoxon-Rank Sum test for “age at diagnosis” and Fisher's exact test for
the other variables.
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tumor subtypes (clades 1 and 2), we found that genes upregulated in
clade 2 samples had significant enrichment of genes involved in
histidine metabolism (adjusted P = .04, Table S6). Genes upregulated
in clade 1 samples showed strongest enrichment for a set of genes
found to be upregulated in a mouse model of lymphoma exhibiting
an immature B-cell immunophenotype; however, this was not
significant after correction for multiple hypothesis testing, suggesting
weak or spurious association (Table S7) [24].
Molecular Subgroup Analyses
The two molecular subgroups, termed clades 1 and 2, divided the
study population with nearly a 1:2 ratio. The patient characteristics of
the two ULMS molecular subgroups are summarized in Table 1.
There were no statistical differences between clades in key variables
for all cases combined including age, primary or recurrent specimen,
tumor stage, tumor size, mitotic index, or adjuvant treatment, with
28% receiving adjuvant chemotherapy, radiation, or combination
modality therapy. There were also no significant differences in these
key variables when examining the primary LMS samples indepen-
dently (Table 2).
The clinical outcome of primary ULMS tumors was examined
separately from recurrent tumors to remove lead-time bias. Age, stage,
and clade for all primary tumors were each found to be associated with
RFS (Table 3). Clade 2 primary ULMS tumors had a superior median
RFS compared to clade 1 (26 months vs 4 months; P = .018; HR,
0.33; Figure 2a). Multivariate analysis was limited to two variables
due to the small number of events (n = 17). Stage and clade when
modeled together were both associated with RFS for primary ULMS
tumors (Table 3). Due to some co-linearity between age and clade, in
a combined model, RFS was not statistically associated with either
variable (Table 3). Only clade was associated with OS for primary
ULMS (Table 4). Patients in clade 2 had a superior median OS
compared to patients in clade 1 (77 months vs 18 months; P = .037;
HR, 0.33; Figure 2b).
For recurrent ULMS tumors, there were no differences between
molecular subgroups with regard to age, International Federation of
Gynecology and Obstetrics (FIGO) stage, grade, size, mitotic index, or
adjuvant therapy (Table S8).When analyzing all recurrent specimens forclinical outcome from the time of collection of the recurrent specimen,
clade was not associated with PFS or OS (Figure S4, A and B).
Discussion
ULMS is an aggressive malignancy with limited treatment options.
Management is made even more challenging because the behavior of
ULMS is unpredictable. Even when the tumor is confined to the
uterus, recurrence and metastasis are common; yet some patients have
indolent metastatic disease associated with prolonged survival
[25,26]. Better understanding of the biology of ULMS through
clinically useful molecular markers will help to determine prognosis
and treatment. In this study, we measured gene expression in a
discovery cohort of fresh-frozen ULMS and NL specimens to identify
a distinct separation between these tissue types. We identified a
predominance of cell cycle genes overexpressed in ULMS that can
serve as potential therapeutic targets. There was a further division and
external validation of ULMS specimens into two reproducible
molecular subtypes that correlated with PFS and OS in primary
tumor specimens, which has potential clinical applications.
Figure 2. (a) RFS by clade for primary tumors. (b) OS by clade for
primary tumors.
Table 3B. RFS in Primary Tumors: Bivariate Model for Stage and Clade
Variable HR (95% CI) P Value
FIGO stage: II/ III/IV versus I 3.56 (1.21-10.49) .02
Clade: clade 2 versus clade 1 0.29 (0.10-0.80) .02
Table 3A. Univariate RFS Analysis Result for Primary Tumors
Variable N Progression
No.
5-Year RFS Rate
(95% CI)
Hazard Ratio
(95% CI)
P Value
All primary patients 24 17 24.3% (8.9-43.8%)
Age at diagnosis 1.04 (1-1.09) .05
FIGO stage
I 14 8 34.6%
(10.1-61.1%)
Ref. level .02
II/III/IV 10 9 10% (0.6-35.8%) 3.11
(1.13-8.58)
Clade
Clade 1 9 8 11.1% (0.6-38.8%) Ref. level .02
Clade 2 15 9 32.1% (9.5-57.9%) 0.33
(0.12-0.86)
Size
≤10 cm 13 10 15.4% (1.2-45.3%) Ref. level .71
N10 cm 11 7 30% (7.1-57.8%) 1.2 (0.45-3.22)
Mitotic index (five missing)
≤20 13 7 46.2% (19.2-69.6%) Ref. level .38
N20 6 5 NR 1.66 (0.52-5.28)
Abbreviation: CI, Confidence interval.
P values were obtained by usingWald test based on Cox proportional hazards model for “age at diagnosis”
and the log-rank test for the other variables.
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between ULMS and NL. Genome-wide expression profiling had
previously been employed in a small study of only four ULMS
samples to identify a few differentially expressed probe sets that were
able to cluster samples into ULMS, leiomyomas, or NL [9]. In that
study, there were 13 genes with expression greater than five-fold
higher in ULMS compared with NL, with six (CDKN2A, CKS2,
FOXM1, PTTG1, TOP2A, and UBE2C) also being part of our
validation gene set, supporting the generalizability of our findings.
Similarly, a recent publication listed the 30 most upregulated genes in
ULMS compared to NL [27]. Sixteen of those 30 genes (ASPM,
BUB1, CCNB2, CDC20, CDKN2A, CDKN3, CENPF, CKS2,
HCAP-G, HMMR, NUSAP1, PTTG1, TOP2A, TTK, TYMS,
UBE2C) were also part of our external validation gene set.
Most of the significantly overexpressed genes in our external
validation gene set had function within the cell cycle. Previous
immunohistochemistry studies from our center have also shown
differential expression of apoptotic and cell cycle regulatory proteins
(p53, p21, and bax) in ULMS compared to benign smooth muscle
tumors [10]. Numerous cell cycle inhibitors currently in early-phase
clinical trials are promising agents for ULMS patients given the findings
in this present study and supported by evidence from previous reports.
A recent study used a small-molecule inhibitor of the mitotic spindle
checkpoint protein Aurora kinase A to inhibit tumor growth in an
orthotopic ULMS model [27]. These data highlight the critical
importance of cell cycle genes in uterine leiomyosarcomagenesis.
Beyond the distinction of ULMS from NL, we now suggest that
ULMS can be further subdivided into molecular clades with clinical
associations. Given the variable and unpredictable behavior of
morphologically similar ULMS tumors confined to the uterus at
diagnosis, this new knowledge may assist with correlative studies on
prospective clinical trials. A recent phase 2 trial by Hensley et al.
observed a 78% PFS at 2 years in women with high-grade uterus-
limited ULMS after adjuvant treatment with gemcitabine plus
docetaxel followed by doxorubicin [28]. A randomized trial to
compare adjuvant chemotherapy with observation is ongoing
([Gynecologic Oncology Group] GOG-277, NCT01533207). Our
results provide a framework to help determine which patients may
benefit from adjuvant therapy.
Our findings are supported by previous reports in non-gynecologic
LMS. In a study of 51 combined primary and recurrent LMS
specimens, of which only 16 were uterine in origin, gene expression
profiling identified three clades with select markers found to be
associated with clinical outcome [13]. Twelve genes identified as
overlapping between our study and the previous report by Beck et al.
indicate concordance between the good and poor prognostic groups
of both studies. Our findings are restricted to a homogeneous set ofTable 3C. RFS in Primary Tumors: Bivariate Model for Age and Clade
Variable HR (95% CI) P Value
Age at diagnosis 1.03 (0.99-1.08) .19
Clade: clade 2 versus clade 1 0.45 (0.16-1.26) .13
Table 4. Univariate OS Analysis Result for Primary Tumors
Variable N Death
No.
5-Year OS Rate
(95% CI)
Hazard Ratio
(95% CI)
P Value *
All primary patients 24 14 44.7% (23-64.4%)
Age at diagnosis 1.04 (0.99-1.09) .14
FIGO stage
I 14 8 51.3% (21.4-74.9%) Ref. level .61
II/III/IV 10 6 33.3% (6.3-64.6%) 1.32 (0.45-3.82)
Clade
Clade 1 9 7 22.2% (3.4-51.3%) Ref. level .04
Clade 2 15 7 57.8% (24.8-80.5%) 0.33 (0.11-0.98)
Size
≤10 cm 13 8 48.5% (17.9-73.7%) Ref. level .59
N10 cm 11 6 40% (12.3-67%) 1.34 (0.46-3.89)
Mitotic index (five missing)
≤20 13 5 59.3% (27.5-81%) Ref. level .09
N20 6 5 40% (5.2-75.3%) 2.85 (0.82-9.89)
* P values were obtained by using Wald test based on Cox proportional hazards model for “age at
diagnosis” and the log-rank test for the other variables.
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mixed LMS population. Although we have separated our survival
analyses into primary and recurrent specimens to reduce lead time
and other biases, this study is still limited by a modest sample size due
to the rarity of this disease. ULMS is often diagnosed incidentally
after a myomectomy or hysterectomy, resulting in challenges to
collecting a homogeneous population of primarily resected specimens
at a referral center.
Several studies have also attempted to better understand the biology
of soft tissue sarcoma and LMS specifically but generally without focus
on ULMS. Some have noted the high expression of muscle-associated
genes in a molecular subgroup that contained mixed origin LMS
specimens [13]. The existence of a muscle-enriched subtype was also
reported in a gene expression profiling study of 40 unselected LMS
samples with an unknown number of ULMS specimens, if any [29].
These results support our findings of overexpression of muscle-related
genes in clade 2 of our molecular subgroups (Table S9).
Other studies have combined morphologic variables of tumor size
and mitotic index in combination with biomarkers Ki67 and Bcl-2 to
distinguish two groups of ULMS with different prognosis [14]. In the
present study, we have differentiated molecular profiles between
ULMS and benign myometrium, confirmed the importance of cell
cycle deregulation in sarcomagenesis, and further subdivided tumors
into two reproducible and externally validated clades associated with
clinical outcome.
Our findings from multiple data sets and orthogonal technologies
add knowledge to a disease that is poorly understood and has a 5-year
survival rate for organ-confined disease of b50% [2]. There is
currently no evidence for any survival advantage from administration
of adjuvant therapy, but the classification of ULMS into clinically
relevant molecular subgroups may begin to identify a subgroup of
patients who may benefit from adjuvant treatment. The key role that
cell cycle genes play in uterine leiomyosarcomagenesis could help to
direct the cell cycle inhibitors currently in early-phase clinical trials
toward this patient population. The molecular subgrouping and
association with survival in ULMS specimens must be further
validated in clinical trials with coordinated biospecimen collection.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.12.007.References
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